Reacta Healthcare appoints Richard Nagle as chair to support growth strategy

Daniel Bevan - Editor

Subscribe to the Businessin Wales daily newsletter for FREE here.

Deeside-based diagnostics company Reacta Healthcare has appointed life sciences entrepreneur Richard Nagle as Chair of its Board of Directors.

The company, which develops food allergy diagnostic products, said Nagle’s arrival comes at a key stage in its growth as it seeks to scale internationally and advance its innovation pipeline.

Nagle brings more than 30 years’ experience across the pharmaceutical, biotechnology and medical technology sectors, including expertise in immunology.

Over his career, he has founded and led multiple companies, secured tens of millions of dollars in investment and overseen operational transformations during periods of rapid growth.

Among his previous leadership roles, he served as Strategic Advisor and CEO at Immune Regulation, now Revolo Biotherapeutics and formerly Peptinnovate, where he led strategic development, clinical programmes and corporate growth initiatives.

Professor Ashley Woodcock, a co-founder of Reacta Healthcare who has served as chair since the company’s inception, will remain with the business as a non-executive director.

Dr Paul Abrahams, Reacta Healthcare CEO, said: “We are thrilled to have Richard join us at such a pivotal time in the Company’s growth trajectory.

“His specific knowledge in the immunology space and broad experience in finance, corporate strategy and product development adds huge value and strengthens our strategic leadership.

“The senior team and I are looking forward to working with Richard to refine and deliver on an ambitious strategy for 2026 and beyond.

“We are hugely grateful to Ashley for his entrepreneurial leadership, guidance and support of Reacta to date and look forward to his ongoing contribution to the business as a Non-Executive Director.”

Richard Nagle, Reacta Healthcare Chair added: “This is an extremely exciting time for Reacta, and I am delighted to be joining this dynamic business.

“Reacta has been at the forefront of food allergy diagnostics R&D and counts many of the leading companies in the allergy therapeutic development space as its partners.

“Our aim now is to continue to expand our presence both in the UK and internationally, delivering solutions that improve the safety, accuracy and efficiency of food allergy testing.

“Reacta has built a world class team to execute on its future development goals, and I look forward to working with Paul and the management team in helping them to realise maximum value from its pioneering products and deep innovation pipeline.”

The appointment follows a period of rapid growth for the company, which was recently ranked 12th in the The Sunday Times Tech100 list of fastest-growing private technology companies for 2026, after expanding its multi-allergen product range to include milk and egg alongside its established peanut challenge meals.